共 237 条
[11]
Sampalis JS(2012)Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials Eur J Cancer 48 3082-3092
[12]
Adachi JD(2013)Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial Osteoporos Int 24 227-235
[13]
Rampakakis E(2020)Denosumab failure associated with escape from suppression of bone resorption (in Eng) Bone 131 371-378
[14]
Vaillancourt J(2005)Precision assessment and radiation safety for dual-energy X-ray absorptiometry: position paper of the International Society for Clinical Densitometry J Clin Densitom 8 247-257
[15]
Karellis A(2013)Diagnostic criteria for primary osteoporosis: year 2012 revision J Bone Miner Metab 31 285-289
[16]
Kindundu C(2004)Reproducibility of bone mineral density measurement in daily practice Ann Rheum Dis 63 462-468
[17]
McClung MR(2004)Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study J Bone Miner Metab 22 191-198
[18]
Lewiecki EM(2020)A 3-year postmarketing study on the safety and effectiveness of once-monthly risedronate in Japanese patients with osteoporosis Osteoporos Sarcopenia 6 439-446
[19]
Cohen SB(2012)Three years of treatment with minodronate in patients with postmenopausal osteoporosis J Bone Miner Metab 30 69-72
[20]
Bolognese GC(2018)Efficacy, safety, and compliance of ibandronate treatment for 3 years in postmenopausal Japanese women with primary osteoporosis Osteoporos Sarcopenia 4 50-56